(CDAX, Software/IT, IVX GR)



| Buy | _ | Value Indic DCF: |
|------------------|-----------|-------------------------------------|
| EUR 31.00 | | Market Sna |
| Price Upside | EUR 27.80 | Market cap: No. of shares EV: |
| opolao | 11.5 /0 | Freefloat MC: |

| Value Indicators: | EUR | Warburg ESG Risk Score: | 2.3 | Description: | | |
|---------------------|----------|-------------------------|--------|-------------------------------------------------------------------|-------|--|
| DCF: | 31.42 | ESG Score (MSCI based): | 3.0 | InVision is a leading supplier of software for WFM and for online | | |
| | | Balance Sheet Score: | 4.0 | | | |
| | | Market Liquidity Score: | 0.0 | training | | |
| Market Snapshot: | EUR m | Shareholders: | | Key Figures (WRe): | 2021e | |
| Market cap: | 62.1 | Freefloat | 37.3 % | Beta: | 2.0 | |
| No. of shares (m): | 2.2 | Peter Bollenbeck | 17.0 % | Price / Book: | 7.9 x | |
| EV: | 66.4 | InVision Holding GmbH | 16.1 % | Equity Ratio: | 47 % | |
| Freefloat MC: | 23.2 | Matthias Schroer | 11.3 % | | | |
| Ø Trad. Vol. (30d): | 16.82 th | Armand Zohari | 10.0 % | | | |

Workforce increase begins

| Stated Figure | es Q1/2021 | : | | | | | |
|---------------|------------|--------|-------|-------|-------|------|-------|
| in EUR m | Q1/21 | Q1/21e | Q1/20 | yoy | 2021e | 2020 | yoy |
| Sales | 3.3 | 3.4 | 3.2 | 3.7% | 14.0 | 12.8 | 10.0% |
| EBIT | 0.2 | 0.3 | 0.2 | -6.9% | -1.1 | 1.1 | - |
| margin | 5.2% | 8.8% | 5.8% | | -8.0% | 8.9% | |

Comment on Figures:

- InVision AG presented the business figures for the first quarter of 2021 on May 6.
- These fell slightly short of expectations, but this shortfall is insignificant for the overall annual forecast, which is characterized by considerable new hires. However, the sales expectation for the current year now represents the upper end of the possible range for 2021.


The company is in the throes of implementing the new growth strategy announced in the context of the annual figures. This can be seen in the number of employees, which now amounts to just over 130 compared to 118 at the end of 2020.

The core of the new strategy is a reorientation towards strong growth. The company plans to invest significantly in the expansion of its business activities over the next five years. An essential part of the investment programme is the hiring of up to 400 additional employees. For 2021, the main focus is on the massive expansion of capacities in customer service, marketing and related areas (see Comment dated 26.03.21).

With regard to the new strategy, Great Britain appears to be showing particular success from today's perspective. Here, it is already possible for newly hired employees to quickly show an operating performance of 300 to 500 new Injixo-seats (EUR 19 per month). In the USA, on the other hand, restitution is currently still in the foreground, while in Germany the effort is still, for the most part, concentrating on the migration of existing customers.

It is, of course, not yet possible to assess the implementation of the growth strategy on the basis of the announced quarterly figures as it takes time for the impact of new employees to become apparent in the sales figures. For the years 2022 to 2025, the company expects annual growth of at least 30% (subscription sales). InVision expects sales of at least EUR 50m and an EBIT margin of more than 25% in 2025. Our forecasts for the growth rates are well below those of the company.

The price target remains unchanged at EUR 31. On this basis, the share continues to be rated Buy.





| Rel. Performance vs CDAX: | |
|---------------------------|--------|
| 1 month: | 1.8 % |
| 6 months: | 26.7 % |
| Year to date: | 26.8 % |
| Trailing 12 months: | 17.4 % |
| Company events: | |

| Company events: | |
|-----------------|-----|
| 28.05.21 | AGM |
| 26.08.21 | Q2 |
| 04.11.21 | Q3 |
| | |

| FY End: 31.12. | CAGR | | | | | | | |
|---------------------|----------|--------|---------|---------|---------|--------|---------|---------|
| in EUR m | (20-23e) | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
| Sales | 19.8 % | 13.2 | 13.1 | 12.6 | 12.8 | 14.0 | 17.5 | 21.9 |
| Change Sales yoy | | 5.9 % | -0.7 % | -3.4 % | 1.1 % | 10.0 % | 25.0 % | 25.0 % |
| Gross profit margin | | 98.9 % | 98.6 % | 100.0 % | 100.0 % | 98.5 % | 98.5 % | 98.5 % |
| EBITDA | - | 1.9 | 0.8 | 1.7 | 1.8 | -0.6 | -2.5 | -2.1 |
| Margin | | 14.3 % | 6.3 % | 13.6 % | 14.1 % | -4.5 % | -14.5 % | -9.5 % |
| EBIT | - | 1.4 | 0.2 | 1.0 | 1.1 | -1.1 | -3.2 | -2.8 |
| Margin | | 10.4 % | 1.8 % | 7.8 % | 8.9 % | -8.0 % | -18.0 % | -13.0 % |
| Net income | - | 8.0 | -0.2 | 2.9 | 0.3 | -0.8 | -2.1 | -1.9 |
| EPS | - | 0.36 | -0.09 | 1.32 | 0.13 | -0.37 | -0.96 | -0.87 |
| EPS adj. | - | 0.36 | -0.09 | 1.32 | 0.13 | -0.37 | -0.96 | -0.87 |
| DPS | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Yield | | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| FCFPS | | 0.03 | -0.16 | 0.73 | 0.39 | 0.05 | -0.65 | -0.62 |
| FCF / Market cap | | 0.1 % | -0.7 % | 4.1 % | 2.0 % | 0.2 % | -2.3 % | -2.2 % |
| EV / Sales | | 5.0 x | 3.6 x | 3.1 x | 3.3 x | 4.7 x | 3.9 x | 3.2 x |
| EV / EBITDA | | 35.3 x | 57.9 x | 23.0 x | 23.5 x | n.a. | n.a. | n.a. |
| EV / EBIT | | 48.5 x | 203.6 x | 40.3 x | 37.3 x | n.a. | n.a. | n.a. |
| P/E | | 83.2 x | n.a. | 13.4 x | 148.3 x | n.a. | n.a. | n.a. |
| P / E adj. | | 83.2 x | n.a. | 13.4 x | 148.3 x | n.a. | n.a. | n.a. |
| FCF Potential Yield | | 1.1 % | 0.1 % | 10.0 % | 2.4 % | -0.4 % | -2.2 % | -1.7 % |
| Net Debt | | -0.7 | -0.4 | 0.0 | -0.8 | 4.3 | 5.7 | 7.1 |
| ROCE (NOPAT) | | 9.8 % | n.a. | 28.9 % | 3.3 % | n.a. | n.a. | n.a. |
| Guidance: n | ı.a. | | | | | | | |








Company Background

- InVision supplies call centre employees with workforce management software and e-learning solutions
- Since 2011 InVision has been providing new cloud-based software products (software as a service, SaaS, cloud) which represent an increasingly important source of earnings for the company

Competitive Quality

- InVision has many years of experience in the call centre and WFM field
- Cloud-based products were further developed in 2011, making InVision a first mover in the field of cloud-based WFM solutions. This was also the case for the firm's second product range, cloud-based training
- The products in the field of SaaS possesses a very modern software architecture and structure (decentralised approach)
- Significant market entry barriers posed are development costs, acquired customer base and technological lead (first mover)
- The SaaS model is mainly of interest for the huge market of smaller users.



InVision



| DCF model | | | | | | | | | | | | | | |
|-----------------------------|---------|-----------|----------|--------|---------------------|--------|--------|--------|--------|--------|--------|--------|-------------|---------|
| | Detaile | d forecas | t period | | Transitional period | | | | | | | | Term. Value | |
| Figures in EUR m | 2021e | 2022e | 2023e | 2024e | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e | 2032e | 2033e | |
| Sales | 14.0 | 17.5 | 21.9 | 27.4 | 34.2 | 41.1 | 48.5 | 55.8 | 63.0 | 68.1 | 71.5 | 75.0 | 78.8 | |
| Sales change | 10.0 % | 25.0 % | 25.0 % | 25.0 % | 25.0 % | 20.0 % | 18.0 % | 15.0 % | 13.0 % | 8.0 % | 5.0 % | 5.0 % | 5.0 % | 3.0 % |
| EBIT | -1.1 | -3.2 | -2.8 | 0.0 | 5.1 | 8.2 | 12.1 | 13.9 | 15.8 | 17.0 | 17.9 | 18.8 | 19.7 | |
| EBIT-margin | -8.0 % | -18.0 % | -13.0 % | 0.0 % | 15.0 % | 20.0 % | 25.0 % | 25.0 % | 25.0 % | 25.0 % | 25.0 % | 25.0 % | 25.0 % | |
| Tax rate (EBT) | 35.0 % | 35.0 % | 35.0 % | 30.0 % | 25.0 % | 20.0 % | 20.0 % | 20.0 % | 20.0 % | 20.0 % | 20.0 % | 20.0 % | 20.0 % | |
| NOPAT | -0.7 | -2.1 | -1.9 | 0.0 | 3.9 | 6.6 | 9.7 | 11.2 | 12.6 | 13.6 | 14.3 | 15.0 | 15.8 | |
| Depreciation | 0.5 | 0.6 | 0.8 | 0.5 | 0.7 | 0.8 | 1.0 | 1.1 | 1.3 | 1.4 | 1.4 | 1.5 | 1.6 | |
| in % of Sales | 3.5 % | 3.5 % | 3.5 % | 2.0 % | 2.0 % | 2.0 % | 2.0 % | 2.0 % | 2.0 % | 2.0 % | 2.0 % | 2.0 % | 2.0 % | |
| Changes in provisions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Change in Liquidity from | | | | | | | | | | | | | | |
| - Working Capital | -0.6 | -0.2 | 0.6 | 0.5 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.3 | 0.2 | 0.2 | 0.2 | |
| - Capex | 0.1 | 0.1 | 0.1 | 0.5 | 0.7 | 8.0 | 1.0 | 1.1 | 1.3 | 1.4 | 1.4 | 1.5 | 1.6 | |
| Capex in % of Sales | 0.8 % | 0.6 % | 0.5 % | 2.0 % | 2.0 % | 2.0 % | 2.0 % | 2.0 % | 2.0 % | 2.0 % | 2.0 % | 2.0 % | 2.0 % | |
| Other | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Free Cash Flow (WACC Model) | 0.2 | -1.3 | -1.8 | -0.5 | 3.5 | 6.2 | 9.3 | 10.8 | 12.2 | 13.4 | 14.1 | 14.8 | 15.6 | 16 |
| PV of FCF | 0.2 | -1.1 | -1.3 | -0.3 | 2.0 | 3.2 | 4.3 | 4.4 | 4.4 | 4.3 | 4.0 | 3.8 | 3.5 | 38 |
| share of PVs | | -3.17 % | | | | | | 48.23 | 3 % | | | | | 54.94 % |

| Model parameter | | | | Valuation (m) | | | |
|--------------------------|---------|---------------------|------|----------------------------|----|-----------------------|-------|
| Derivation of WACC: | | Derivation of Beta: | | Present values 2033e | 31 | | |
| | | | | Terminal Value | 38 | | |
| Debt ratio | 0.00 % | Financial Strength | 2.00 | Financial liabilities | 7 | | |
| Cost of debt (after tax) | 4.2 % | Liquidity (share) | 2.00 | Pension liabilities | 0 | | |
| Market return | 7.00 % | Cyclicality | 2.00 | Hybrid capital | 0 | | |
| Risk free rate | 1.50 % | Transparency | 2.00 | Minority interest | 0 | | |
| | | Others | 2.00 | Market val. of investments | 0 | | |
| | | | | Liquidity | 8 | No. of shares (m) | 2.2 |
| WACC | 12.50 % | Beta | 2.00 | Equity Value | 70 | Value per share (EUR) | 31.42 |

| Sens | itivity Va | lue per Sh | are (EUR |) | | | | | | | | | | | | | |
|-----------------------------------|------------|------------|----------|--------|--------|--------|--------|--------|------|--------|---------|---------|---------|---------|---------|---------|---------|
| Terminal Growth Delta EBIT-margin | | | | | | | | | | | | | | | | | |
| Beta | WACC | 2.25 % | 2.50 % | 2.75 % | 3.00 % | 3.25 % | 3.50 % | 3.75 % | Beta | WACC | -1.5 pp | -1.0 pp | -0.5 pp | +0.0 pp | +0.5 pp | +1.0 pp | +1.5 pp |
| 2.18 | 13.5 % | 26.12 | 26.41 | 26.72 | 27.04 | 27.38 | 27.73 | 28.10 | 2.18 | 13.5 % | 25.01 | 25.69 | 26.36 | 27.04 | 27.72 | 28.39 | 29.07 |
| 2.09 | 13.0 % | 28.04 | 28.38 | 28.73 | 29.11 | 29.50 | 29.92 | 30.35 | 2.09 | 13.0 % | 26.95 | 27.67 | 28.39 | 29.11 | 29.83 | 30.55 | 31.27 |
| 2.05 | 12.8 % | 29.08 | 29.44 | 29.83 | 30.23 | 30.66 | 31.11 | 31.58 | 2.05 | 12.8 % | 28.00 | 28.75 | 29.49 | 30.23 | 30.97 | 31.72 | 32.46 |
| 2.00 | 12.5 % | 30.17 | 30.57 | 30.98 | 31.42 | 31.88 | 32.37 | 32.88 | 2.00 | 12.5 % | 29.12 | 29.88 | 30.65 | 31.42 | 32.19 | 32.95 | 33.72 |
| 1.95 | 12.3 % | 31.32 | 31.75 | 32.20 | 32.68 | 33.18 | 33.71 | 34.27 | 1.95 | 12.3 % | 30.30 | 31.09 | 31.88 | 32.68 | 33.47 | 34.26 | 35.06 |
| 1.91 | 12.0 % | 32.54 | 33.01 | 33.50 | 34.01 | 34.56 | 35.13 | 35.74 | 1.91 | 12.0 % | 31.55 | 32.37 | 33.19 | 34.01 | 34.83 | 35.65 | 36.48 |
| 1.82 | 11.5 % | 35.20 | 35.75 | 36.33 | 36.94 | 37.58 | 38.27 | 39.00 | 1.82 | 11.5 % | 34.29 | 35.17 | 36.05 | 36.94 | 37.82 | 38.70 | 39.58 |

- Moderate demand for cloud solutions are the basis for the revenue and earnings expectations.
- Potential is expected in the SaaS/Cloud area, which should continually increase its share of revenues.
- A tax-optimised company structure and high loss carry-forwards have an additional positive effect.

InVision



| Valuation | | | | | | | |
|-------------------------------------|---------|---------|--------|---------|---------|--------|--------|
| | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
| Price / Book | 6.4 x | 4.7 x | 3.0 x | 3.2 x | 7.9 x | 10.8 x | 16.4 x |
| Book value per share ex intangibles | 4.49 | 4.41 | 5.06 | 5.27 | 2.79 | 1.83 | 0.95 |
| EV / Sales | 5.0 x | 3.6 x | 3.1 x | 3.3 x | 4.7 x | 3.9 x | 3.2 x |
| EV / EBITDA | 35.3 x | 57.9 x | 23.0 x | 23.5 x | n.a. | n.a. | n.a. |
| EV / EBIT | 48.5 x | 203.6 x | 40.3 x | 37.3 x | n.a. | n.a. | n.a. |
| EV / EBIT adj.* | 48.5 x | 203.6 x | 40.3 x | 37.3 x | n.a. | n.a. | n.a. |
| P/FCF | 909.7 x | n.a. | 24.2 x | 49.8 x | 514.5 x | n.a. | n.a. |
| P/E | 83.2 x | n.a. | 13.4 x | 148.3 x | n.a. | n.a. | n.a. |
| P / E adj.* | 83.2 x | n.a. | 13.4 x | 148.3 x | n.a. | n.a. | n.a. |
| Dividend Yield | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| FCF Potential Yield (on market EV) | 1.1 % | 0.1 % | 10.0 % | 2.4 % | -0.4 % | -2.2 % | -1.7 % |
| *Adjustments made for: - | | | | | | | |

| Company Specific Items | | | | | | | | | | | |
|----------------------------------------------|------|------|------|------|-------|-------|-------|--|--|--|--|
| | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e | | | | |
| Market Potential Cloud Computing (Gartner) | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | | | | |
| Market Potential Cloud Computing (Forrester) | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | | | | |





| Consolidated profit & loss | | | | | | | |
|--------------------------------------------------|--------|--------|---------|---------|--------|---------|---------|
| In EUR m | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
| Sales | 13.2 | 13.1 | 12.6 | 12.8 | 14.0 | 17.5 | 21.9 |
| Change Sales yoy | 5.9 % | -0.7 % | -3.4 % | 1.1 % | 10.0 % | 25.0 % | 25.0 % |
| Increase / decrease in inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Own work capitalised | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Sales | 13.2 | 13.1 | 12.6 | 12.8 | 14.0 | 17.5 | 21.9 |
| Material expenses | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.3 | 0.3 |
| Gross profit | 13.0 | 12.9 | 12.6 | 12.8 | 13.8 | 17.3 | 21.6 |
| Gross profit margin | 98.9 % | 98.6 % | 100.0 % | 100.0 % | 98.5 % | 98.5 % | 98.5 % |
| Personnel expenses | 8.1 | 8.7 | 8.2 | 8.7 | 11.9 | 16.7 | 19.7 |
| Other operating income | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 |
| Other operating expenses | 3.1 | 3.5 | 2.9 | 2.3 | 2.7 | 3.3 | 4.2 |
| Unfrequent items | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITDA | 1.9 | 0.8 | 1.7 | 1.8 | -0.6 | -2.5 | -2.1 |
| Margin | 14.3 % | 6.3 % | 13.6 % | 14.1 % | -4.5 % | -14.5 % | -9.5 % |
| Depreciation of fixed assets | 0.5 | 0.6 | 0.7 | 0.7 | 0.5 | 0.6 | 0.8 |
| EBITA | 1.4 | 0.2 | 1.0 | 1.1 | -1.1 | -3.2 | -2.8 |
| Amortisation of intangible assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Goodwill amortisation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT | 1.4 | 0.2 | 1.0 | 1.1 | -1.1 | -3.2 | -2.8 |
| Margin | 10.4 % | 1.8 % | 7.8 % | 8.9 % | -8.0 % | -18.0 % | -13.0 % |
| EBIT adj. | 1.4 | 0.2 | 1.0 | 1.1 | -1.1 | -3.2 | -2.8 |
| Interest income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest expenses | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Other financial income (loss) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBT | 1.3 | 0.2 | 0.9 | 1.0 | -1.3 | -3.3 | -3.0 |
| Margin | 10.1 % | 1.7 % | 7.0 % | 7.7 % | -9.1 % | -18.8 % | -13.7 % |
| Total taxes | 0.4 | 0.5 | -2.1 | 0.6 | -0.4 | -1.2 | -1.0 |
| Net income from continuing operations | 0.9 | -0.2 | 3.0 | 0.4 | -0.8 | -2.1 | -1.9 |
| Income from discontinued operations (net of tax) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income before minorities | 0.8 | -0.2 | 2.9 | 0.3 | -0.8 | -2.1 | -1.9 |
| Minority interest | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income | 0.8 | -0.2 | 2.9 | 0.3 | -0.8 | -2.1 | -1.9 |
| Margin | 6.1 % | -1.5 % | 23.3 % | 2.3 % | -5.9 % | -12.3 % | -8.9 % |
| Number of shares, average | 2.2 | 2.2 | 2.2 | 2.2 | 2.2 | 2.2 | 2.2 |
| EPS | 0.36 | -0.09 | 1.32 | 0.13 | -0.37 | -0.96 | -0.87 |
| EPS adj. | 0.36 | -0.09 | 1.32 | 0.13 | -0.37 | -0.96 | -0.87 |
| *Adjustments made for: | | | | | | | |


Guidance: n.a.

Source: Warburg Research

| Financial Ratios | | | | | | | | |
|-------------------------------|---------|---------|----------|---------|---------|---------|---------|--|
| | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e | |
| Total Operating Costs / Sales | 85.7 % | 93.7 % | 86.4 % | 85.9 % | 104.5 % | 114.5 % | 109.5 % | |
| Operating Leverage | -10.4 x | 113.2 x | -93.2 x | 14.8 x | n.a. | 7.2 x | -0.4 x | |
| EBITDA / Interest expenses | 46.9 x | 105.0 x | 15.9 x | 12.1 x | n.m. | n.m. | n.m. | |
| Tax rate (EBT) | 33.0 % | 205.4 % | -236.9 % | 62.1 % | 35.0 % | 35.0 % | 35.0 % | |
| Dividend Payout Ratio | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | |
| Sales per Employee | 106,153 | 107,988 | 104,273 | 105,391 | 115,930 | 144,913 | 181,141 | |








Source: Warburg Research

Source: Warburg Research



| Consolidated balance sheet | | | | | | | |
|---------------------------------------------------------|------|------|------|------|-------|-------|------|
| In EUR m | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023 |
| Assets | | | | | | | |
| Goodwill and other intangible assets | 0.3 | 0.3 | 1.8 | 1.6 | 1.6 | 1.7 | 1.7 |
| thereof other intangible assets | 0.3 | 0.3 | 1.8 | 1.6 | 1.6 | 1.7 | 1.7 |
| thereof Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Property, plant and equipment | 9.6 | 9.3 | 8.9 | 8.9 | 8.5 | 8.0 | 7.4 |
| Financial assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other long-term assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets | 9.9 | 9.6 | 10.8 | 10.6 | 10.2 | 9.7 | 9.0 |
| Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Accounts receivable | 1.3 | 1.4 | 1.2 | 1.2 | 0.6 | 0.5 | 0.6 |
| Liquid assets | 2.2 | 0.7 | 2.6 | 7.8 | 2.7 | 1.7 | 0.3 |
| Other short-term assets | 0.2 | 0.4 | 3.7 | 2.9 | 3.4 | 3.4 | 3.4 |
| Current assets | 3.7 | 2.4 | 7.5 | 11.8 | 6.7 | 5.6 | 4.3 |
| Total Assets | 13.7 | 12.1 | 18.2 | 22.4 | 16.9 | 15.3 | 13.4 |
| Liabilities and shareholders' equity | | | | | | | |
| Subscribed capital | 2.2 | 2.2 | 2.2 | 2.2 | 2.2 | 2.2 | 2.2 |
| Capital reserve | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 |
| Retained earnings | 0.0 | 0.0 | 0.0 | 0.0 | -0.8 | -3.0 | -4.9 |
| Other equity components | 7.0 | 6.8 | 9.7 | 10.0 | 5.3 | 5.3 | 5.3 |
| Shareholders' equity | 10.4 | 10.2 | 13.1 | 13.4 | 7.9 | 5.7 | 3.8 |
| Minority interest | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total equity | 10.4 | 10.2 | 13.1 | 13.4 | 7.9 | 5.7 | 3.8 |
| Provisions | 0.3 | 0.4 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
| thereof provisions for pensions and similar obligations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Financial liabilities (total) | 1.5 | 0.3 | 2.6 | 7.0 | 7.0 | 7.5 | 7.5 |
| Short-term financial liabilities | 0.0 | 0.3 | 0.5 | 1.0 | 1.0 | 1.0 | 1.0 |
| Accounts payable | 0.1 | 0.3 | 0.2 | 0.1 | 0.1 | 0.2 | 0.2 |
| Other liabilities | 1.4 | 1.0 | 2.1 | 1.7 | 1.7 | 1.7 | 1.7 |
| Liabilities | 3.3 | 1.9 | 5.1 | 9.0 | 9.0 | 9.6 | 9.6 |
| Total liabilities and shareholders' equity | 13.7 | 12.1 | 18.2 | 22.4 | 16.9 | 15.3 | 13.4 |


| Financial Ratios | | | | | | | |
|-------------------------------------|--------|--------|--------|--------|----------------|---------|---------|
| | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
| Efficiency of Capital Employment | | | | | | | |
| Operating Assets Turnover | 1.2 x | 1.3 x | 1.3 x | 1.3 x | 1.6 x | 2.1 x | 2.8 x |
| Capital Employed Turnover | 1.4 x | 1.3 x | 1.0 x | 1.0 x | 1.2 x | 1.5 x | 2.0 x |
| ROA | 8.1 % | -2.1 % | 27.4 % | 2.7 % | -8.1 % | -22.2 % | -21.6 % |
| Return on Capital | | | | | | | |
| ROCE (NOPAT) | 9.8 % | n.a. | 28.9 % | 3.3 % | n.a. | n.a. | n.a. |
| ROE | 7.6 % | -1.9 % | 25.3 % | 2.2 % | -7.8 % | -31.5 % | -40.9 % |
| Adj. ROE | 7.6 % | -1.9 % | 25.3 % | 2.2 % | <i>-</i> 7.8 % | -31.5 % | -40.9 % |
| Balance sheet quality | | | | | | | |
| Net Debt | -0.7 | -0.4 | 0.0 | -0.8 | 4.3 | 5.7 | 7.1 |
| Net Financial Debt | -0.7 | -0.4 | 0.0 | -0.8 | 4.3 | 5.7 | 7.1 |
| Net Gearing | -6.8 % | -4.1 % | 0.1 % | -5.8 % | 54.3 % | 99.7 % | 187.8 % |
| Net Fin. Debt / EBITDA | n.a. | n.a. | 0.6 % | n.a. | n.a. | n.a. | n.a. |
| Book Value / Share | 4.6 | 4.6 | 5.9 | 6.0 | 3.5 | 2.6 | 1.7 |
| Book value per share ex intangibles | 4.5 | 4.4 | 5.1 | 5.3 | 2.8 | 1.8 | 1.0 |





| Consolidated cash flow statement | | | | | | | |
|--------------------------------------------------------|------|------|------|------|-------|-------|-------|
| In EUR m | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
| Net income | 0.8 | -0.2 | 2.9 | 0.3 | -0.8 | -2.1 | -1.9 |
| Depreciation of fixed assets | 0.5 | 0.6 | 0.7 | 0.7 | 0.5 | 0.6 | 0.8 |
| Amortisation of goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Amortisation of intangible assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Increase/decrease in long-term provisions | -0.3 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
| Other non-cash income and expenses | -0.5 | -0.3 | -2.7 | -0.1 | 0.0 | 0.0 | 0.0 |
| Cash Flow before NWC change | 0.5 | 0.2 | 1.1 | 1.0 | -0.3 | -1.5 | -1.2 |
| Increase / decrease in inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Increase / decrease in accounts receivable | 0.1 | -0.1 | 0.2 | 0.0 | 0.6 | 0.1 | -0.1 |
| Increase / decrease in accounts payable | 0.0 | 0.1 | 0.1 | -0.1 | 0.0 | 0.1 | 0.0 |
| Increase / decrease in other working capital positions | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Increase / decrease in working capital (total) | 0.1 | -0.1 | 0.3 | -0.1 | 0.6 | 0.2 | -0.1 |
| Net cash provided by operating activities [1] | 0.7 | 0.0 | 1.5 | 0.9 | 0.2 | -1.3 | -1.3 |
| Investments in intangible assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Investments in property, plant and equipment | 0.6 | 0.3 | -0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
| Payments for acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Financial investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Income from asset disposals | 0.0 | 0.0 | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net cash provided by investing activities [2] | -0.6 | -0.3 | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 |
| Change in financial liabilities | -0.8 | -1.3 | 2.4 | 4.4 | 0.0 | 0.4 | 0.0 |
| Dividends paid | -1.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Purchase of own shares | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Capital measures | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other | 0.0 | 0.0 | -1.8 | -0.1 | 0.0 | 0.0 | 0.0 |
| Net cash provided by financing activities [3] | -1.9 | -1.3 | 0.6 | 4.3 | 0.0 | 0.4 | 0.0 |
| Change in liquid funds [1]+[2]+[3] | -1.8 | -1.6 | 1.9 | 5.2 | 0.1 | -1.0 | -1.4 |
| Effects of exchange-rate changes on cash | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cash and cash equivalent at end of period | 2.2 | 0.7 | 2.6 | 7.8 | 2.7 | 1.7 | 0.3 |

| Financial Ratios | | | | | | | |
|--------------------------------------|------------|---------|---------|----------|---------|---------|---------|
| | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e |
| Cash Flow | | | | | | | |
| FCF | 0.1 | -0.3 | 1.6 | 0.9 | 0.1 | -1.4 | -1.4 |
| Free Cash Flow / Sales | 0.6 % | -2.7 % | 12.9 % | 6.8 % | 0.9 % | -8.2 % | -6.3 % |
| Free Cash Flow Potential | 0.8 | 0.0 | 3.9 | 1.0 | -0.3 | -1.5 | -1.1 |
| Free Cash Flow / Net Profit | 9.2 % | 174.8 % | 55.3 % | 300.9 % | -14.6 % | 67.2 % | 71.4 % |
| Interest Received / Avg. Cash | 0.0 % | 0.0 % | 1.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Interest Paid / Avg. Debt | 2.1 % | 0.9 % | 7.5 % | 3.1 % | 2.1 % | 2.1 % | 2.0 % |
| Management of Funds | | | | | | | |
| Investment ratio | 4.6 % | 2.7 % | 1.2 % | 0.6 % | 0.8 % | 0.6 % | 0.5 % |
| Maint. Capex / Sales | 4.6 % | 2.7 % | -1.2 % | 0.6 % | 0.8 % | 0.6 % | 0.5 % |
| Capex / Dep | 117.1 % | 61.0 % | 21.0 % | 11.9 % | 22.4 % | 17.9 % | 14.3 % |
| Avg. Working Capital / Sales | 9.3 % | 8.7 % | 8.4 % | 8.1 % | 5.6 % | 2.3 % | 1.6 % |
| Trade Debtors / Trade Creditors | 1090.9 % | 520.8 % | 715.4 % | 1246.2 % | 600.0 % | 250.0 % | 300.0 % |
| Inventory Turnover | 149682.0 x | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| Receivables collection period (days) | 35 | 39 | 34 | 33 | 16 | 10 | 10 |
| Payables payment period (days) | 283 | 551 | 20,390 | 69,417 | 173 | 278 | 222 |
| Cash conversion cycle (Days) | -248 | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |



Source: Warburg Research Source: Warburg Research Source: Warburg Research



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

InVision



SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The Warburg ESG Risk Score is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation
- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

| Company | Disclosure | Link to the historical price targets and rating changes (last 12 months) | | | | |
|----------|------------|--------------------------------------------------------------------------|--|--|--|--|
| InVision | 5 | http://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005859698.htm | | | | |



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

| -B- | Buy: | The price of the analysed financial instrument is expected to rise over the next 12 months. |
|------------|-------------------|-----------------------------------------------------------------------------------------------------------|
| -H- | Hold: | The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months. |
| -S- | Sell: | The price of the analysed financial instrument is expected to fall over the next 12 months. |
| <u>"_"</u> | Rating suspended: | The available information currently does not permit an evaluation of the company. |

| Rating | Number of stocks | % of Universe |
|------------------|------------------|---------------|
| Buy | 144 | 69 |
| Hold | 56 | 27 |
| Sell | 5 | 2 |
| Rating suspended | 5 | 2 |
| Total | 210 | 100 |

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

| Rating | Number of stocks | % of Universe |
|------------------|------------------|---------------|
| Buy | 40 | 83 |
| Hold | 5 | 10 |
| Sell | 0 | 0 |
| Rating suspended | 3 | 6 |
| Total | 48 | 100 |

PRICE AND RATING HISTORY INVISION AS OF 07.05.2021



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



| EQUITIES | | | |
|------------------------------------------------|--------------------------------------------------------|----------------------------------------|------------------------------------------------------|
| Matthias Rode Head of Equities | +49 40 3282-2678 mrode@mmwarburg.com | | |
| RESEARCH | | | |
| Michael Heider | +49 40 309537-280 | Philipp Kaiser | +49 40 309537-260 |
| Head of Research | mheider@warburg-research.com | Real Estate | pkaiser@warburg-research.com |
| Henner Rüschmeier | +49 40 309537-270 | Thilo Kleibauer | +49 40 309537-257 |
| Head of Research Stefan Augustin | hrueschmeier@warburg-research.com +49 40 309537-168 | Retail, Consumer Goods Eggert Kuls | tkleibauer@warburg-research.com +49 40 309537-256 |
| Cap. Goods, Engineering | saugustin@warburg-research.com | Engineering | ekuls@warburg-research.com |
| Jan Bauer | +49 40 309537-155 | Andreas Pläsier | +49 40 309537-246 |
| Renewables | jbauer@warburg-research.com | Banks, Financial Services | aplaesier@warburg-research.com |
| Jonas Blum Telco, Media, Construction | +49 40 309537-240 jblum@warburg-research.com | Malte Schaumann Technology | +49 40 309537-170 mschaumann@warburg-research.com |
| Christian Cohrs | +49 40 309537-175 | Oliver Schwarz | +49 40 309537-250 |
| Industrials & Transportation | ccohrs@warburg-research.com | Chemicals, Agriculture | oschwarz@warburg-research.com |
| Dr. Christian Ehmann BioTech, Life Science | +49 40 309537-167 | Simon Stippig Real Estate | +49 40 309537-265 |
| Felix Ellmann | cehmann@warburg-research.com +49 40 309537-120 | Cansu Tatar | sstippig@warburg-research.com +49 40 309537-248 |
| Software, IT | fellmann@warburg-research.com | Cap. Goods, Engineering | ctatar@warburg-research.com |
| Jörg Philipp Frey | +49 40 309537-258 | Marc-René Tonn | +49 40 309537-259 |
| Retail, Consumer Goods | jfrey@warburg-research.com | Automobiles, Car Suppliers | mtonn@warburg-research.com |
| Marius Fuhrberg Financial Services | +49 40 309537-185 mfuhrberg@warburg-research.com | Robert-Jan van der Horst Technology | +49 40 309537-290 rvanderhorst@warburg-research.com |
| Mustafa Hidir | +49 40 309537-230 | Andreas Wolf | +49 40 309537-140 |
| Automobiles, Car Suppliers | mhidir@warburg-research.com | Software, IT | awolf@warburg-research.com |
| Ulrich Huwald | +49 40 309537-255 | | |
| Health Care, Pharma | uhuwald@warburg-research.com | | |
| INSTITUTIONAL EQU | ITY SALES | | |
| Marc Niemann | +49 40 3282-2660 | Maximilian Martin | +49 69 5050-7413 |
| Head of Equity Sales, Germany Klaus Schilling | mniemann@mmwarburg.com +49 40 3282-2664 | Austria, Poland Christopher Seedorf | mmartin@mmwarburg.com +49 69 5050-7414 |
| Head of Equity Sales, Germany | kschilling@mmwarburg.com | Switzerland | cseedorf@mmwarburg.com |
| Tim Beckmann | +49 40 3282-2665 | | |
| United Kingdom | tbeckmann@mmwarburg.com | | |
| Lea Bogdanova United Kingdom, Ireland | +49 69 5050-7411 lbogdanova@mmwarburg.com | | |
| Jens Buchmüller | +49 69 5050-7415 | | |
| Scandinavia, Austria | jbuchmueller@mmwarburg.com | | |
| Alexander Eschweiler | +49 40 3282-2669 | Sophie Hauer | +49 69 5050-7417 |
| Germany, Luxembourg | aeschweiler@mmwarburg.com | Roadshow/Marketing | shauer@mmwarburg.com |
| Matthias Fritsch United Kingdom | +49 40 3282-2696 mfritsch@mmwarburg.com | Juliane Niemann Roadshow/Marketing | +49 40 3282-2694 jniemann@mmwarburg.com |
| | | | jeee |
| SALES TRADING | | | |
| Oliver Merckel Head of Sales Trading | +49 40 3282-2634 | Marcel Magiera Sales Trading | +49 40 3282-2662 |
| Elyaz Dust | omerckel@mmwarburg.com +49 40 3282-2702 | Bastian Quast | mmagiera@mmwarburg.com +49 40 3282-2701 |
| Sales Trading | edust@mmwarburg.com | Sales Trading | bquast@mmwarburg.com |
| Michael Ilgenstein | +49 40 3282-2700 | Jörg Treptow | +49 40 3282-2658 |
| Sales Trading | milgenstein@mmwarburg.com | Sales Trading | jtreptow@mmwarburg.com |
| MACRO RESEARCH | | | |
| Carsten Klude Macro Research | +49 40 3282-2572 | Dr. Christian Jasperneite | +49 40 3282-2439 |
| | cklude@mmwarburg.com | Investment Strategy | cjasperneite@mmwarburg.com |
| Our research can be | | | |
| Warburg Research | research.mmwarburg.com/en/index.html | Thomson Reuters | www.thomsonreuters.com |
| Bloomberg | RESP MMWA GO | Capital IQ | www.capitaliq.com |
| FactSet | www.factset.com | | |
| For access please conta | act: | | |
| Andrea Schaper | +49 40 3282-2632 | Kerstin Muthig | +49 40 3282-2703 |
| Sales Assistance | aschaper@mmwarburg.com | Sales Assistance | kmuthig@mmwarburg.com |
| | | | |